Assoc. Prof. Dr. Fadime Canbolat | Health Research | Best Researcher Award

Assoc. Prof. Dr. Fadime Canbolat | Canakkale Onsekiz Mart University | Turkey

Assoc. Prof. Dr. Fadime Canbolat is an accomplished Associate Professor of Pharmaceutical Toxicology with over a decade of academic, research, and laboratory expertise. She has made significant contributions to pharmacology, toxicology, therapeutic drug monitoring, precision medicine, and medical biotechnology. Throughout her career, she has successfully combined teaching, research, and laboratory management roles, demonstrating strong leadership in curriculum development, analytical method validation, bioanalytical studies, and risk assessment. With a proven track record of supervising graduate students, leading research projects, and publishing in reputed journals, Assoc. Prof. Dr. Fadime Canbolat has established herself as a dedicated scholar committed to advancing pharmaceutical sciences. Her multidisciplinary background integrates toxicological analysis, pharmacogenetics, and clinical pharmacology, enabling her to contribute meaningfully to both academic and applied research domains.

Professional Profile

ORCID

GOOGLE SCHOLAR

SCOPUS

Summary of Suitability

Assoc. Prof. Dr. Fadime Canbolat is a distinguished researcher, academician, and pharmaceutical toxicologist with professional and research experience in pharmacology, toxicology, precision medicine, and therapeutic drug monitoring. Her contributions span across academic teaching, advanced laboratory research, drug validation, nanoparticle-based drug delivery systems, molecular pharmacogenetics, and risk assessment studies, making her a highly qualified candidate for the Best Researcher Award.

Education

Assoc. Prof. Dr. Fadime Canbolat holds a Ph.D. in Pharmaceutical Toxicology from Yeditepe University, where her doctoral research focused on assessing the relationship between drug levels and cytochrome P450 enzyme activities in patients with genetic polymorphisms, integrating therapeutic drug monitoring and personalized medicine approaches. She also earned a Master’s degree in Pharmacology and Toxicology from Selçuk University, where she evaluated drug use patterns and prescription costs. Additionally, she pursued another Master’s degree in Visual Communication and Design at Uskudar University, enhancing her ability to integrate scientific visualization in medical research. Her undergraduate studies in Chemistry at Selçuk University provided a strong foundation in analytical sciences, which she later applied extensively in her toxicology research and teaching.

Experience

Assoc. Prof. Dr. Fadime Canbolat is currently serving as a Faculty Member at Canakkale Onsekiz Mart University, where she teaches and mentors students in pharmaceutical toxicology, pharmacology, and forensic sciences. Previously, she spent over eight years at Uskudar University’s Clinical Pharmacogenetics & Advanced Toxicology Laboratory, where she served as Laboratory Assistant Manager and later as Quality Manager. She successfully managed validation studies for therapeutic drug monitoring, developed analytical methods for various drug molecules, and contributed to the accreditation of the Advanced Toxicology Laboratory under ISO/IEC 17025 standards. Her teaching portfolio is equally extensive, having delivered courses in neuropharmacology, toxicology, pharmacogenetics, forensic chemistry, food-drug interactions, and instrumental analysis. She has also supervised numerous graduate students, guiding them in pharmacology, toxicology, and medical biotechnology research.

Research Interests

Assoc. Prof. Dr. Fadime Canbolat research interests span across several domains, including pharmaceutical toxicology, precision medicine, therapeutic drug monitoring (TDM), cytochrome P450 enzyme phenotyping, bioanalytical method development, and medical biotechnology. She is particularly focused on the clinical application of pharmacogenetics to optimize drug therapy based on individual genetic profiles. Her work also explores nanoparticle-based drug delivery systems, green synthesis of nanoparticles for biomedical applications, and risk assessment of elemental impurities in pharmaceuticals and dietary supplements. Furthermore, she is actively involved in evaluating antioxidant activity, genotoxicity, and molecular mechanisms underlying neurodegenerative and psychiatric disorders, making her research highly interdisciplinary and clinically relevant.

Awards

Assoc. Prof. Dr. Fadime Canbolat has received several recognitions for her academic and research contributions, including invitations to serve as a reviewer and editorial board member for international journals in pharmaceutical sciences. She has successfully led multiple competitive scientific research projects funded by national and institutional bodies, including studies on nanoparticle-based drug delivery systems, neuroprotective agents, precision medicine, and risk assessments in food and pharmaceuticals. Her innovative approach to integrating advanced analytical techniques with clinical pharmacology has positioned her as a leader in her field, making her a strong candidate for prestigious research awards.

Publication Top Notes

Chitosan Nanoparticles Loaded with Quercetin and Valproic Acid: A Novel Approach for Enhancing Antioxidant Activity against Oxidative Stress in the SH-SY5Y Human Neuroblastoma Cell Line

Comparison of Normal saline, Activated Charcoal and Intravenous Lipid Emulsion in a Rat Model of Colchicine Overdose: Experimental Study

Analysis of non-carcinogenic health risk assessment of elemental impurities in vitamin C supplements

Chitosan Nanoparticle Loaded with Quercetin and Valproic Acid: A Novel Approach for Enhancing Antioxidant Activity against Oxidative Stress in SH-SY5Y Cell Line

Evaluation of the Antidepressant Effect of Propolis in Chronic Unpredictable Mild Stress-induced Depression Model in Rats

Conclusion

Assoc. Prof. Dr. Fadime Canbolat is a highly dedicated academic and researcher whose contributions to pharmaceutical toxicology and pharmacogenetics are both innovative and impactful. Her extensive experience in research, teaching, laboratory management, and quality assurance demonstrates her leadership in advancing scientific knowledge and improving clinical practices. With an exceptional record of peer-reviewed publications, project leadership, and active involvement in multidisciplinary studies, she continues to make significant contributions to precision medicine, toxicological risk assessment, and nanoparticle-based drug delivery systems. Assoc. Prof. Dr. Fadime Canbolat commitment to scientific excellence, student mentorship, and collaborative research positions her as an outstanding candidate for award nomination, reflecting her influence on the advancement of pharmaceutical sciences globally.

Assoc. Prof. Dr. Irene Ruengkhachorn | Medicine | Women Researcher Award

Associate Professor at Faculty of Meidicine Siriraj Hospital, Mahidol university, Thailand

Dr. Irene Ruengkhachorn is a dedicated academic and clinical specialist in gynecologic oncology, currently serving as an Associate Professor at the Faculty of Medicine Siriraj Hospital, Mahidol University. With nearly two decades of medical and teaching experience, she has significantly contributed to the field through research, clinical practice, and education. Dr. Ruengkhachorn’s expertise spans minimally invasive surgery, integrative oncology, and advanced gynecologic cancer treatment protocols. Her scholarly activities have earned her recognition within the national and international medical community, where she continues to drive progress in women’s cancer care.

Profile

Education

Dr. Ruengkhachorn has pursued a thorough and distinguished academic journey. She earned her Doctor of Medicine degree from the Faculty of Medicine Siriraj Hospital, Mahidol University, in 2000. She continued her postgraduate training at the same institution, completing graduate diplomas in Basic and Clinical Sciences in 2004 and 2005, respectively. She further specialized by earning a Thai Board certification in Obstetrics and Gynecology in 2006, and in Gynecologic Oncology from Chiangmai University in 2008. Her interest in surgical techniques led her to complete certifications in gynecologic laparoscopic surgery in 2012 and undergo visiting clinical training in minimally invasive surgery at Mayo Clinic, USA, the same year. In 2017, she added a Certificate of Advanced Medical Epidemiology from Thammasat University, equipping her with robust research design and analysis capabilities.

Experience

Dr. Ruengkhachorn began her academic career as an Instructor in 2009 at Siriraj Hospital, advancing to Assistant Professor in 2013 and later to Associate Professor in 2016. Over the years, she has played a central role in mentoring medical students and residents, particularly in gynecologic oncology rotations. Prior to her tenure at Siriraj Hospital, she also served as a tutor in the Gynecologic Oncology Department at Chiangmai University. Her long-standing service in one of Thailand’s leading tertiary care centers has enabled her to influence treatment protocols and participate in numerous multi-disciplinary teams that shape national cancer care standards.

Research Interest

Dr. Ruengkhachorn’s research interests are grounded in the clinical challenges of gynecologic oncology. She focuses on cervical and ovarian cancer management, outcomes of surgical interventions, and predictive biomarkers. Her work extends into evaluating oncologic outcomes, the role of pathology in treatment planning, and recently, integrating artificial intelligence and precision medicine approaches. She has also explored minimally invasive surgical techniques, HPV-related cytological abnormalities, and the role of traditional medicine in cancer care. Her aim is to translate clinical findings into practice guidelines that improve survival and quality of life for women affected by reproductive cancers.

Award

Her research has received multiple accolades that highlight both scientific rigor and relevance. In 2008, she won the GSK Research Award for her work on predicting the need for adjuvant radiotherapy in early-stage cervical cancer. The R2R Research Award followed in 2014, recognizing her investigation into atypical glandular cells in cytology. In 2017, she earned the “Research of the Month” title at Siriraj Hospital for her landmark study on outcomes of advanced cervical carcinoma treated with chemotherapy at a tertiary referral center. These honors underscore her contributions to evidence-based gynecologic oncology in high-incidence settings.

Publication

Dr. Ruengkhachorn has published extensively in peer-reviewed journals. Seven representative publications include:

Ruengkhachorn I et al., “Oncologic outcomes of stage IVB or persistent or recurrent cervical carcinoma patients treated with chemotherapy,” Int J Gynecol Cancer, 2016, cited 49 times.

Ittiamornlert P, Ruengkhachorn I, “Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes,” BMC Cancer, 2019, cited 61 times.

Ruengkhachorn I et al., “Undiagnosed uterine sarcomas identified during surgery for presumed leiomyoma,” Int J Gynecol Cancer, 2017, cited 34 times.

Ruengkhachorn I et al., “Comparison of oncologic outcomes of unanticipated cervical carcinoma,” Gynecol Oncol, 2019, cited 57 times.

Phianpiset R, Ruengkhachorn I et al., “ASCCP risk-based colposcopy recommendations in Thai women,” Obstet Gynecol, 2020, cited 66 times.

Ruengkhachorn I et al., “Predicting factors associated with resistance to Methotrexate in GTN,” Asian Pac J Clin Oncol, 2022, cited 23 times.

Ruengkhachorn I et al., “High-risk HPV genotyping in atypical squamous cells,” Scientific Reports, 2023, cited 15 times.
These publications reflect her diverse yet focused contributions in clinical oncology and diagnostic advancement.

Conclusion

Dr. Irene Ruengkhachorn has emerged as a leader in gynecologic oncology in Thailand through her relentless pursuit of clinical excellence, academic advancement, and translational research. Her academic path, enriched by international exposure and cross-disciplinary integration, positions her at the forefront of modern cancer care. As she continues to mentor young physicians, publish impactful research, and lead clinical innovation, Dr. Ruengkhachorn exemplifies the synergy of research and compassionate care in advancing women’s health. Her ongoing engagement with global research communities ensures her contributions remain both relevant and far-reaching in the evolving field of gynecologic oncology.